Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and m

Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Gilead Sciences and Merck said on Tuesday their experimental once-weekly HIV pill kept the virus sup

The recommendations of Wall Street analysts are often relied on by investors when deciding whether t

FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck

Andra AP fonden trimmed its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 14.9% in the fi

Merck (MRK) concluded the recent trading session at $124.4, signifying a -2.43% move from its prior

For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yie

Dimensional Fund Advisors LP lifted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 23.

Many think the next standard cancer treatment will pair two innovations.

AIA Group Ltd lowered its stake in Merck and Co., Inc. (NYSE: MRK) by 1.7% during the undefined quar

Allspring Global Investments Holdings LLC reduced its position in shares of Merck and Co., Inc. (NYS

Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch

Merck shares climb after the FDA approved Lipfendra, the first oral PCSK9 inhibitor for lowering LDL

The FDA's approval of Merck (NYSE:MRK | MRK Price Prediction) enlicitide decanoate, marketed as Lipf

Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Ph

Health stocks had a strong week, with some big firms seeing drugs approved. Eli Lilly (LLY) reported

Shares of Merck & Co., Inc. (MRK) rise 3,453% since 1990 thanks to institutional investors.

On Thursday, the U.S. Food and Drug Administration (FDA) approved Merck & Co Inc.'s (NYSE:MRK) LIPFE

Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL c

The pill, branded as Lipfendra, is intended to treat patients with hypercholesterolemia, including t

4:15pm: Semiconductor selloff Wall Street ended lower on Thursday, with semiconductor stocks leading

11:50am: AI stocks out of favor Investors are still favoring stocks with little direct exposure to A

Merck said on Thursday the U.S. FDA has approved its cholesterol pill, the first of its kind to rece

At week 24 in the CORALreef Lipids and CORALreef HeFH trials, LIPFENDRA significantly reduced LDL-C

It's the first pill that lowers blood cholesterol far better than statins—medicines that a quarter o

Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins

RAHWAY, N.J.--(BUSINESS WIRE)--Merck's LIPFENDRA is the First and Only Once-Daily Oral PCSK9 Inhibit

Merck & Co Inc. (NYSE:MRK) on Wednesday released topline data from the Phase 3 KEYNOTE‑C93 trial of

Merck's Phase 3 KEYNOTE-C93 trial showed Keytruda improved progression-free survival over chemot

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data on Daily, Weekly, and Monthly

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the Phase 3

JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises t

BMO Capital analyst Evan David Seigerman maintains Merck & Co (NYSE:MRK) with a Outperform an

Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the pric

Merck & Co. shares are in focus Monday after a wave of analyst activity capped by a new FDA appr

Morgan Stanley analyst Terence Flynn maintains Merck & Co (NYSE:MRK) with a Equal-Weight and

Scott urges Trump admin to increase tariffs on Chinese generic drug makers, citing forced labor &amp

RBC Capital analyst Trung Huynh reiterates Merck & Co (NYSE:MRK) with a Outperform and mainta

Wall St analysts changed outlook on top names. KBW cut AON PT to $400, Barclay's cut T PT to $24

Wells Fargo analyst Mohit Bansal maintains Merck & Co (NYSE:MRK) with a Overweight and raises

HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Cantor Fitzgerald analyst Carter Gould reiterates Merck & Co (NYSE:MRK) with a Neutral and ma

B of A Securities analyst Tim Anderson maintains Merck & Co (NYSE:MRK) with a Buy and raises

Scotiabank analyst Louise Chen maintains Merck & Co (NYSE:MRK) with a Sector Outperform and r

US lawmakers probe Merck and AbbVie over national security and ethical risks tied to clinical trials

Agreement will help state ADAP programs provide access to IDVYNSO™ (doravirine/islatravir) for eligi